Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Atorvastatin improves postprandial lipoprotein metabolism in normolipidemic subjects
Autore:
Parhofer, KG; Barrett, PHR; Schwandt, P;
Indirizzi:
Univ Munich, Klinikum Grosshadern, Dept Internal Med 2, D-81377 Munich, Germany Univ Munich Munich Germany D-81377 ternal Med 2, D-81377 Munich, Germany Univ Western Australia, Dept Med, Perth, WA 6000, Australia Univ Western Australia Perth WA Australia 6000 Perth, WA 6000, Australia
Titolo Testata:
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
fascicolo: 11, volume: 85, anno: 2000,
pagine: 4224 - 4230
SICI:
0021-972X(200011)85:11<4224:AIPLMI>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRIGLYCERIDE-RICH LIPOPROTEINS; APOLIPOPROTEIN-B SECRETION; COA REDUCTASE INHIBITORS; LOW-DENSITY LIPOPROTEIN; RETINYL PALMITATE; PRIMARY HYPERCHOLESTEROLEMIA; MINIATURE PIGS; VITAMIN-A; C-III; LOVASTATIN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
44
Recensione:
Indirizzi per estratti:
Indirizzo: Parhofer, KG Univ Munich, Klinikum Grosshadern, Dept Med 2, Marchioninistr15, D-81377 Munich, Germany Univ Munich Marchioninistr 15 Munich Germany D-81377 Germany
Citazione:
K.G. Parhofer et al., "Atorvastatin improves postprandial lipoprotein metabolism in normolipidemic subjects", J CLIN END, 85(11), 2000, pp. 4224-4230

Abstract

Atorvastatin is a potent HMG:CoA reductase inhibitor that decreases low-density lipoprotein (LDL) cholesterol and fasting triglyceride concentrations. Because of the positive association between elevated postprandial lipoproteins and atherosclerosis, we investigated the effect of atorvastatin on postprandial lipoprotein metabolism. The effect of 4 weeks of atorvastatin therapy (10 mg/day) was evaluated in 10 normolipidemic men (30 +/- 2 yr; bodymass index, 22 +/- 3 kg/m(2); cholesterol, 4.84 +/- 0.54 mmol/L; triglyceride, 1.47 +/- 0.50 mmol/L; high-density lipoprotein cholesterol, 1.17 +/- 0.18 mmol/L; LDL-cholesterol, 3.00 +/- 0.49 mmol/L). Postprandial lipoprotein metabolism was evaluated with a standardized fat load (1300 kcal, 87% fat, 7% carbohydrates, 6% protein, 80,000 IU vitamin A) given after 12 h fast. Plasma was obtained every 2 h for 14 h. A chylomicron (CM) and a chylomicron-remnant (CR) fraction was isolated by ultracentrifugation, and triglycerides, cholesterol, apolipoprotein B, apoB-48, and retinyl-palmitate were determined in plasma and in each lipoprotein fraction. Atorvastatin therapy significantly (P < 0.001) decreased fasting cholesterol (-28%), triglycerides (-30%), LDL-cholesterol (-41%), and apolipoprotein B (-39%), whereas high-density lipoprotein cholesterol increased (4%, not significant). The area under the curve for plasma triglycerides (-27%) and CR triglycerides (-40%), cholesterol (-49%), and apoB-48 (-43%) decreased significantly (P < 0.05), whereas CR retinyl-palmitate decreased (-34%) with borderline significance (P = 0.08). However, none of the CM parameters changed with atorvastatin therapy. This indicates that, in addition to improving fasting lipoprotein concentrations, atorvastatin improves postprandial lipoprotein metabolism presumably by increasing CR clearance or by decreasing the conversion of CMsto CRs, thus increasing the direct removal of CMs from plasma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 11:15:52